Analyst consensus rating
IRulya Therapeutics Analyst Rating: Strong Buy
Direct answer
IRulya Therapeutics's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $75.00.
Forecast evidence checked October 20, 2026.
Get free IRulya Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $38.45
- Average price target
- $75.00
- High price target
- $98.00
- Low price target
- $65.00
- Low target gap
- +69.1%
- Target upside
- +95.1%
- High target gap
- +154.9%
- Target range width
- 85.8%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- October 20, 2026
- Valid through
- October 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for IRulya Therapeutics?
IRulya Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $75.00.
How far are IRulya Therapeutics's low and high targets from the recorded price?
The low target implies +69.1%, while the high target implies +154.9%.
How many analysts are included in IRulya Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is IRulya Therapeutics's target upside or downside calculated?
The average target of $75.00 is divided by the recorded price of $38.45, then one is subtracted to produce +95.1%. This does not guarantee a future return.
When was IRulya Therapeutics's analyst forecast verified?
The data was verified on 2026-10-20. The dataset is valid through 2026-10-27.